Claim: A Facebook post lists multiple dramatic assertions about “cassavarin.” They claim that a 340-patient trial conducted by the University of Ghana Medical School (UGMS) showed that 71% of type 2 diabetics reversed the disease and ditched insulin within 90 days.
Verdict: False! UGMS emphatically states no such trial or compound exists. Searches of the medical literature reveal no published studies on cassavarin or any Ghanaian cassava drug.
Full Text
A flurry of recent social media posts, with over 4,000 shares on Facebook, has claimed that Ghanaian scientists have discovered a cassava-based compound called “cassavarin” that “reverses” type 2 diabetes, boasting a 71% remission rate in a 6-month trial and allowing patients to discontinue insulin within 90 days.
The posts even allege that Big Pharma is suing over patent rights, that the U.S. FDA refused expedited approval, and that Ghana is licensing cassavarin to neighbouring countries. No credible evidence supports any of these claims.
This claim has received multiple responses and mixed reactions.
This fact-check is important because the claim promotes a purported medical breakthrough that could cause serious harm if believed, including encouraging people living with diabetes to abandon proven treatments in favour of an unverified “cure.”
It also attributes the purported scientific breakthrough to respected Ghanaian institutions, which risks undermining public trust in legitimate medical research. It follows a familiar pattern of health misinformation that exploits anti-pharmaceutical sentiment.
By interrogating the claim, DUBAWA helps to protect public health, uphold evidence-based medicine, and prevent the spread of dangerous medical disinformation
Verification
The University of Ghana Medical School felt compelled to respond publicly. On January 18, 2026, it strongly rejected the rumours. UGMS noted it “has not conducted any such study, has not isolated any compound by that name, and has not undertaken clinical trials of the nature described.” The notice warned Ghanaians to rely only on information from official channels, affirming that the “cassavarin” story is misinformation. By providing clear denials, the University has called into question all official scientific claims.
Also, experts note that stopping insulin suddenly can be very dangerous – as the International Diabetes Federation warns, without insulin, “type 1 diabetes is a death sentence,” and many type 2 patients also need it.
Lack of scientific evidence
A key check was the scientific literature: no peer-reviewed journal or conference paper mentions “cassavarin” as a diabetes treatment. Nor is there any record in clinical trial registries. By contrast, medical research on herbal diabetes remedies in Ghana is real – a recent review found 76 medicinal plants under study for blood sugar control – but cassava itself is not among any verified cures.
Cassava is indeed studied for its nutritional properties, mainly for fiber and energy, not as a drug.
For example, a 1999 University of Ghana thesis showed that adult diabetics on medication who ate cassava products for 5 weeks did not experience any harmful increase in blood sugar. No study suggests a cassava component could regenerate insulin-producing cells or reverse diabetes. The idea of “cassavarin” appears to have no scientific basis beyond speculation.
Regulatory and Patent Rumours
All claims of regulatory involvement or legal battles are likewise unsupported. Ghana’s Food and Drugs Authority (FDA) has no record of approving or even evaluating any cassava-based diabetes drug. Internationally, the U.S. FDA has made no statement on “cassavarin” – the alleged expedited review refusal was a fictitious detail from the posts. Similarly, no pharmaceutical company has filed a patent infringement suit against Ghana for the diabetes treatments described. The University’s statement lumps these allegations together as fabrications.
Public Health and Economic Context
According to the International Diabetes Federation, about 2.7% of Ghanaian adults (roughly 317,400 people) have diabetes. This number is growing with urbanisation and lifestyle changes. Managing diabetes can be expensive: studies in Ghana report that a patient may spend the equivalent of GHC 440 per month (~$42) on insulin and supplies. In contrast to viral claims of a $3/month cassava supplement. A genuinely effective, low-cost treatment would indeed be transformative for Ghana and its neighbours. But chasing a nonexistent miracle cure can be dangerous. As the IDF notes, abruptly stopping insulin without medical supervision can be life-threatening.
Across West Africa, where cassava is a dietary staple and diabetes is also on the rise, the hoax underscores the need for reliable health information. So far, no cassava extract has emerged as a cure for diabetes in any scientific study.
Conclusion
In summary, the “cassavarin” saga is a cautionary tale of misinformation. The viral claims of a 71% cure rate and associated lawsuits are false. University of Ghana authorities have made this clear, and no scientific evidence of cassavarin exists. For now, Ghana’s public health focus remains on prevention, screening, and managing diabetes with proven methods – not unverified social-media sensationalism.
